Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Credit: mrinalpal / Shutterstock.com. Indian commercial vehicle manufacturer Tata Motors reported a 6.15% decline in total sales, including both domestic and international markets, with 72,753 ...

Tata, despite a YoY sales decline, has pipped Hyundai to take the third place, selling 45,199 units in the domestic market, followed by Hyundai in third, with 44,374 units sold in India.

The supplemental application is for the addition of extended dosing intervals (up to every 24 weeks) of EYLEA HD injection 8 mg across all approved indications. The FDA disagreed with Regeneron ...

Regeneron Pharmaceuticals ... affordability challenges. Still, EYLEA HD posted a 54% increase in U.S. sales to $307 million, partially offsetting the decline. Dupixent remains a growth driver ...

Regeneron Pharmaceuticals ... a funding gap at copay assistance foundations. With respect to EYLEA, first quarter 2025 U.S. net sales were $736 million, down 39% compared to the first quarter ...

Starting in 2025, the Eylea franchise as a whole began to decline due to ... We assign Regeneron a Medium Morningstar Uncertainty Rating, as its future sales are well diversified with several ...

Regeneron reported quarterly revenue contraction of 4% year on year, which was largely driven by declines in its Eylea franchise. Original dose Eylea declined 39% year on year and 38% sequentially ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to ...

In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...